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Abstract
Backgroud: Cytokine response against hepatitis C virus (HCV) is likely to determine the natural course of infection
as well as the outcome of antiviral treatment. However, the role of particular cytokines remains unclear. The current
study analyzed activation of cytokine response in chronic hepatitis C patients undergoing standard antiviral
treatment.
Methods: Twenty-two patients were treated with pegylated interferon and ribavirin. Twenty-six different cytokine
transcripts were measured quantitatively in peripheral blood mononuclear cells (PBMC) before and after therapy
and correlated with therapy outcome as well as with clinical and liver histological data.
Results: We found that patients who achieved sustained virological response (SVR) showed higher pretreatment
cytokine response when compared to subjects in whom therapy was unsuccessful. The differentially expressed
factors included IL-8, IL-16, TNF-α, GM-CSF, MCP-2, TGF-β, and IP-10. Serum ALT activity and/or histological grading
also positively correlated with the expression of IL-1α, IL-4, IL-6, IL-10, IL-12, IL-15, GM-CSF, M-CSF, MCP-2 and TGF-β.
Conclusion: Pretreatment activation of the immune system, as reflected by cytokines transcripts upregulation,
positively correlates with treatment outcome and closely reflects liver inflammatory activity.
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Background
Despite impressive progress in the therapy of chronic
hepatitis C, accurate prediction of treatment outcome in
an individual patient remains challenging. The well
established predictive factors include viral load, geno-
type, quasispecies characteristics and early virological re-
sponse dynamics [1–3], as well as a number of host
factors like race/ethnicity, age, gender, alcohol consump-
tion and IL-28B gene diversity [4].
The immune response against HCV is considered to
be the principal determinant of the natural course of
infection and it also ultimately determines the outcome
of IFN-based therapies [5–7]. Various pro- and anti-
inflammatory factors and virus inhibiting immune sys-
tem components such as cytokines and their receptors,
were subject of a number of studies. Most attention was
devoted to TNF-α, IFN-γ, IL-6, IL-8, IL-10 [8–13], how-
ever, many other cytokines [14–16] as well as transcrip-
tion factors [17, 18] were also analyzed. A limited
number of studies addressed the issue whether pretreat-
ment levels of cytokines are predictive of outcome.
Thus, in one recent study by Par et al [8] sustained viro-
logical response (SVR) was associated with a baseline in-
creased production of TNF-alpha and IL-6 by TLR-4
activated monocytes and decreased production of IL-4
and IL-10 by PMA activated lymphocytes. These
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findings are in agreements with an earlier study by Ume-
mura et al [10] in which low pretreatment levels of IL-
12 and high levels of IL-10 were found to be predictive
of treatment failure. Similar results were reported by
Yoneda et al [14], who after analyzing 6 different cyto-
kines concluded that low IL-10 and high IL-12 and IL-
18 levels were associated with treatment response. In an-
other study the same group reported that high levels of
eotaxin and macrophage inflammatory protein (MIP)-
1beta were associated with SVR [19]. High level of
serum IL-12 as a predictive factor for SVR was con-
firmed in yet another study [15]. Although patients dif-
fered with respect to clinical, epidemiological, and
ethnical background, the resuts of the above studies sug-
gest that markers of immune activation, in particular
Th1 cytokines, correlate with positive treatment out-
come. However, it was also reported that low IL-6 serum
concentration may be associated with SVR, which is
contrary to other studies [12].
Here we report on the activation of the cytokine re-
sponse in HCV infected patients undergoing antiviral
treatment with pegylated interferon (peg-IFN) and riba-
virin. Twenty-six different gene transcripts were mea-
sured quantitatively in peripheral blood mononuclear
cells (PBMC) before and after therapy, and correlated
with clinical, virological, and histological data.
Methods
Patients
The study group consisted of 22 HIV-negative patients
with chronic hepatitis C presenting at the outpatient
clinic for antiviral treatment. Some clinical, histo-
logical and biochemical data on these patients are
shown in Table 1. Eligible patients were at least
18 year-old, had detectable plasma HCV RNA level
and had not been previously treated for hepatitis C.
Furthermore, patients were required to have no his-
tory of decompensated liver disease, absolute neutro-
phil count of 1500 or more per cubic millimetre,
platelet count at least 70,000 per cubic millimetre,
and haemoglobin level of 12 g or more per decilitre.
Apart from chronic hepatitis, patients were expected
not to have any other clinical conditions which might
have influenced their immune status such as acute or
chronic infections, autoimmune and neoplastic dis-
eases, nor were they receiving any immunosuppressive
treatment. Patients who were current alcohol or drug
abusers were excluded from the study.
Informed consent was obtained from each patient in-
cluded in the study and the study protocol followed eth-
ical guidelines of the 2013 Declaration of Helsinki.
Furthermore, the study was approved by the Ethical
Committee of the Warsaw Medical University.
All patients underwent standard therapy with peg-IFN
alfa-2a 180 μg once weekly (Pagasys; Hoffmann-
LaRoche, Basel, Switzerland) and ribavirin (Rebetol,
Schering-Plough) in the dose of 1000 mg/day or
1200 mg/day if patients body weight was <75 kg or
≥75 kg, respectively. Duration of treatment was 48 weeks
in patients infected with genotypes 1 and 4, and 24 weeks
in patients infected genotype 3. Following current rec-
ommendations, therapy was discontinued in patients
Table 1 Some clinical, virological and biochemical characteristics of the 22 studied patients
Parameter SVR patients (n = 12) Non-responders (n = 10) Statistical significance
Gender (M/F) 6/6 6/4 NS
Age (yr)a 46.3 ± 18.7 46.8 ± 12.8 NS
Baseline viral load (IU/ml) 1.33 × 106 ± 1.28 × 106 1.04 × 106 ± 1.14 × 106 NS
Serum ALT activity (U/L) 94.1 ± 79.9 96.4 ± 50.3 NS
Grading 2.42 ± 0.16 1.92 ± 0.17 P = 0.029
Staging 2.54 ± 0.23 1.88 ± 0.14 P = 0.053
IL28B genotype CC 7 0 P = 0.005
CT 3 7
TT 2 3
Genotype 1b 7 8 NS
3a 4 1
4 1 1
Complianceb 8 (66 %) 7 (70 %)
Leukocytes (109/L) 5.95 ± 2.22 5.80 ± 1.95
Neutrophils (109/L) 3.28 ± 1.51 3.11 ± 1.32
NS not significant
aAll values are means ± SD
b According to the “80/80/80” rule [25]
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who had HCV RNA level decrease <2 log10 from base-
line level at 12 weeks.
The infecting HCV genotype, as determined by INNO-
LiPA assay (Innogenetics, NV, Gent, Belgium), was 1b in
15 (68 %), 3a in five (23 %) and 4 in two (9 %) patients.
Liver biopsy was performed within 2 months preceding
therapy and liver histology was assessed using the
METAVIR scoring system [20].
Viral load quantification was performed at weeks 0,
12, and 48 (Cobas Amplicor HCV Monitor Test v2.0;
Roche Diagnostics). The primary end-point was a sus-
tained virological response (SVR), defined as a negative
HCV RNA level 24 weeks after the end of therapy, when
tested with the above qualitative assay.
DNA samples from patients were genotyped for the
IL-28B rs12979860 polymorphism with commercially
available SNP genotyping platform, the TaqMan SNP
genotyping assays (Applied Biosystems Inc, Foster City,
CA), using the 7500 Fast real-time thermocycler. Taq-
Man probes and primers were identical to those pub-
lished by Lagging et al. [21]. For automated allele calling
SDS software (Applied Biosystems Inc.) was used.
Detection of cytokine transcripts
For the analysis of cytokine transcripts, approximately
3x 105–106 PBMC were isolated from blood by centrifu-
gation over density gradient and RNA was extracted by
means of a modified guanidinium thiocyanate-phenol/
chloroform technique using a commercially available kit
(TRIZOL LS, Gibco/BRL).
Two microliters of reverse transcripton product (equiva-
lent to 3 × 104–105 cells) were directly added into 18 μl
real time PCR mix containing 0.5 μM of each primer,
1.25 μM MgCl2 and 2 μl Master SYBRGreen I (Fast Start
DNA Master SYBRGreen I, Roche Applied Sciences) and
run in Light Cycler as described before [22]. Transcripts
for the following cytokines/chemokines were amplified:
IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12, IL-
15, IL-16, IL-18, TNF-α, HLA-DR, IFNα, IFN-β, GM-CSF,
M-CSF, MCP-1/CCL2, MCP-2/CCL8, MIP-1α/CCL3,
MIP-1β/CCL4, RANTES/CCL5, TGF-β, IP10/CXCL10,
and myxovirus resistance protein A/MxA. The primers
used were described previously [22].
Histone3 rRNA, which is unaffected by cell activation
state, was used to normalize expression of analyzed cyto-
kines transcripts. The calculation of gene expression
level was performed by the 2-ΔΔCT method [23].
Statistical analysis
All data were compared using the nonparametric Mann-
Whitney U test and Spearman’s coefficient was used to
calculate the correlations. Wilcoxon matched-pairs
signed rank test was employed to compare transcript
levels before and after treatment and proportions were
analyzed by Fisher's exact test. P≤ .05 was considered to
be statistically significant. Calculations were performed
using GraphPad Prism version 6 for Windows (Graph-
Pad Software, San Diego California USA). Since multiple
independent tests were run simultaneously, the Benja-
mini–Hochberg procedure (BH step-up procedure) [24]
was used to control for the false discovery rate.
Results
Twelve patients met the criteria of early viral response
(EVR) defined as ≥2 log10 IU/ml reduction of viral load
at 12 weeks of treatment and eventually achieved SVR.
The remaining 10 patients were HCV RNA positive six
months after treatment and were considered non-
responders.
None of the patients had to be withdrawn from ther-
apy due to adverse events, but both Peg-IFN and ribavi-
rin dosage had to be reduced at some time point in a
large proportion of patients. However, when adherence
was measured according to the “80/80/80” rule [25] over
60 % patients complied (Table 1).
The relationship of SVR with demographic, virologic,
and clinical characteristics is shown in Table 1. SVR pa-
tients differed from nonresponders with respect to the
presence of IL28B genotype CC (p = 0.005) and demon-
strated higher histological activity reflected by grading
score (p = 0.029), while the difference in histological sta-
ging was borderline (p = 0.053). Baseline viral load and
genotype as well as patients' age and gender were not
significantly different in SVR patients and non-
responders.
The results of quantitative expression of analyzed
genes in PBMC samples drawn prior to the initiation of
antiviral treatment among SVR patients and non-
responders are presented in Fig. 1. Transcript levels of
analyzed cytokine transcripts were higher in the former
group than in the latter and the differences reached stat-
istical significance (p ≤ 0.05) by Mann Whitney test for
IL-8, IL-16, TNF-α, GM-CSF, MCP-2, TGF-β (Table 2).
However, IP-10 transcripts were higher among non-
responders. Since multiple independent tests were run
simultaneously, we used the Benjamini–Hochberg pro-
cedure (BH step-up procedure) [24] to control for the
false discovery rate (at level 0.05). Using this post hoc
procedure for 26 simultaneous tests, only differences for
IL-8, TNF-α, MCP-2 and IP-10 transcripts remained
significant.
When the same analysis was repeated 6 months after
the end of treatment, there were no significant differ-
ences between the two groups in any of the above pa-
rameters, as all analyzed transcripts fell in both SVR
patients and non-responders (not shown). This drop in
cytokine transcripts was significant (p ≤ 0.05) for IL-8
and TGF-β in the former and for IL-1α and MCP-2 in
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the latter group of patients. However, when correction
for the multiple independent testing was applied, none
of these differences remained significant.
While viral load correlated neither with liver histology
nor ALT activity, there was a significant correlation be-
tween cytokine transcript levels in PBMC and liver bi-
opsy grading scores and serum ALT activity prior to the
initiation of antiviral therapy. Two transcripts (IL-6 and
M-CSF) showed statistically significant correlation with
grading scores and ten (IL-1α, IL-4, IL-6, IL-10, IL-12,
IL-15, GM-CSF, M-CSF, MCP-2 and TGF-β) correlated
with ALT serum activity. However, after application of
Benjamini–Hochberg procedure, only five transcripts
remained significant at the level of 0.05 (IL-4, IL-10, IL-
15, MCP-2 and TGF-β).
Discussion
The effect of IFN-based anti-HCV therapy is believed to
be strongly determined by pro- and anti-inflammatory cy-
tokines constituting part of the innate and adaptive im-
mune response [26]. These are produced by a number of
cells including hepatocytes, stellate cells as well as various
immune cells infiltrating liver tissue [27]. However, they
are also present in peripheral blood as soluble proteins
and as intracellular gene transcripts in PBMC [28–30].
Activation of the immune system, as measured by
serum cytokines and genes expression levels, is com-
monly regarded as an important predictor of therapy
efficacy [8, 10, 11]. Nevertheless, previous approaches
did not define clearly which factors are clinically im-
portant [27].
In the current study we demonstrated that patients
who achieve SVR differ significantly from those in whom
therapy failed with respect to pretreatment immune cell
activation state. Thus, the majority of 26 analyzed tran-
scripts were upregulated in SVR-patients and statistically
significant differences were found for such important
factors as IL-8, IL-16, TNF-α, GM-CSF, MCP-2, TGF-β,
and IP-10. This list includes major pro-inflammatory
mediators known to play a pivotal role in antiviral re-
sponse. Not unexpectedly, SVR-patients had higher ac-
tivity of liver inflammation activity reflected by grading
scores.
Interestingly, the level of IP-10 transcript correlated in-
versely with positive treatment outcome. IP-10 plays a
central role in liver inflammation, and it is expressed in
the HCV-infected liver [31]. In several independent stud-
ies, elevated serum levels of IP-10 were found to predict
the failure of IFN-α–based HCV treatment [32, 33]. This
paradox was explained by showing that IP-10 in the
(See figure on previous page.)
Fig. 1 Real-time PCR analysis of gene transcripts in peripheral blood mononuclear cells (PBMC) from HCV-infected patients prior to
antiviral treatment. Relative quantification of gene expression was calculated using the 2−ΔΔCT method, and all data were normalized to
histone 3 RNA. Solid circles represent patients achieving sustained virological response (SVR), and open circles represent patients who
failed treatment. Horizontal lines indicate median values. Missing data represent situation in which the mRNA was below the detection
limit. IL, Interleukin; TNF, Tumor necrosis factor; HLA-DR, human leukocyte antigen DR1; IFN, Interferon; IP-10, IFN-inducible protein-10;
GM-CSF, Granulocyte-macrophage colony-stimulating factor; M-CSF, Macrophage colony-stimulating factor; MCP, Monocyte chemotactic
protein; MIP, Macrophage inflammatory protein; RANTES, Regulated on activation normal T cell expressed and secreted; TGF, Transforming
growth factor; MxA, Myxovirus resistance protein. *, statistically significant (p ≤ 0.05) by Mann-Whitney U test only; **. statistically significant
(p ≤ 0.05) using Benjamini–Hochberg procedure to correct for multiple testing [24]
Table 2 Correlation between cytokine transcript levels in PBMC and liver biopsy grading scores and ALT activity in 22 patients with
chronic hepatitis C prior to the initiation of antiviral therapy
Cytokinea Liver histology Grading ALT activity in serum
Spearman r Statistical significance Spearman r Statistical significance
IL–1α 0.34 NS 0.62 0.025
IL–4 0.31 NS 0.66 0.002b
IL–6 0.47 0.05 0.46 0.050
IL–10 0.18 NS 0.59 0.005b
IL–12 0.27 NS 0.49 0.028
IL–15 0.19 NS 0.64 0.007b
GM–CSF 0.43 NS 0.49 0.030
M–CSF 0.67 0.010 0.56 0.040
MCP–2 0.28 NS 0.54 0.009b
TGF–β 0.39 NS 0.59 0.004b
aOnly cytokines with p≤ 0.05 are listed
bstatistically significant (p≤ 0.05) using Benjamini–Hochberg procedure to correct for multiple testing [24]
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plasma of many HCV patients is enzymatically processed
to produce a IP-10 receptor antagonist [34].
Our findings are in agreement with studies showing
that the level of immune activation, reflected by the con-
centration of soluble cytokines in serum [10, 14, 15, 19]
or monocytes and lymphocytes culture supernatants [8],
correlate with positive treatment outcome. However,
these studies were limited to a small number of cyto-
kines, whereas we analyzed 26 different cytokine tran-
scripts. While our analysis of PBMC transcripts with
respects to treatment outcome is largely supportive of
the above findings, it is of note that Huang et al [35],
using Affimetrix GeneChip failed to identify any signifi-
cant differences in PBMC gene expression between SVR
and non-SVR patients. Similarly, Younossi et al [36]
found that SVR was associated with higher pretreatment
gene expression levels of cytoplasmic transcription fac-
tors signal transducer and activator of transcription-6
(STAT6) and STAT5 and lower expression level of the
cytokine chemokine ligand-3 (CCL3) and not with the
level of cytokines expression.
In our study activation state of peripheral immune
cells was correlated with two basic and commonly used
markers of liver damage: histological grading and in par-
ticular with ALT activity in serum. Association between
the severity of inflammation and fibrosis and elevation
of TNF-alpha and TGF-beta has been previously re-
ported by Neuman et al [37]. Similarly, IL-18 and IL-2
were correlated with ALT activity by others [38, 39].
Interestingly, ALT activity correlated positively with a
number of pro-inflammatory mediators, but also with
Th2 response markers IL-4 and IL-10. This is not unex-
pected as Cocciarelli et al [11], while measuring circulat-
ing levels of IL-2, IL-4, IL-10 and IFN-gamma, found
that both Th1 but particularly Th2 associated cytokines
IL-4 and IL-10 were dramatically elevated in chronic
hepatitis C. Enhanced Th2 responses during chronic
HCV infection were earlier reported by another group
[40] and very high correlation between ALT activity and
IL-4 level was found by Gramenzi et al [39].
It is widely accepted that liver infiltrating immune
cells are largely responsible for the inflammation and
development of chronic disease [41–43]. Koziel et al.
[44] demonstrated that intrahepatic cytotoxic T lym-
phocytes (CTL) specific for HCV were able to pro-
duce IFN-γ, TNF-α, GM-CSF, IL-8 and IL-10.
Similarly, in a study performed on chimpanzees
acutely infected with HCV, the dynamics of viremia
and course of infection correlated with intrahepatic
accumulation of HCV antigen-specific CD4+ and CD8
+ cells and with their response, as measured by inter-
feron production [45]. Activation of cytokine produc-
tion could be also direct as Li et al. demonstrated
Toll-like receptor-3 dependent induction of RANTES,
MIP-1α, MIP-1β, IP10, and IL-6 by double-stranded
HCV RNA in cultured hepatoma cells [16].
Our findings of close correlation between the immune
activation state of PBMC and liver inflammation
reflected by ALT and HAI scores could indicate that the
functional statuts of PBMC and cells infiltrating the liver
are similar. A supporting evidence comes from studies
performed in acutely infected chimpanzees demonstrat-
ing correlation between HCV-specific CD8 T-cell re-
sponses in the blood and molecular and functional
markers of T-cell responses in the liver [46]. Similary, in
HCV-infected liver transplant recipients, the cytokine
profile of intrahepatic T cells did not differ from that ob-
tained in peripheral blood [47]. Furthermore, a propor-
tion of blood cell population may consist of cells
trafficking between liver and the blood [48, 49].
Since PBMC contain divergent cells, the use of unsep-
arated PBMC could complicate the interpretation of the
results, as pointed out by Hou et al [1]. While PBMC
subpopulations were not analyzed in detail in our study,
major differences were unlikely (Table 1). Furthermore,
any clinical application would benefit from the simplicity
of unseparated PBMC analysis
Among our patients therapy resulted in reduction of
the immune activation state as reflected by the dimin-
ished transcripts level of cytokines. These findings are in
accordance with observation that even unsuccessful
therapy may contribute to quenching of liver tissue in-
flammation in HCV-infected patients [50, 51].
In addition to the expression of cytokines, only IL28B
genotype CC and histological activity were significant
predictors of SVR, while such established factors as pre-
treatment viral load and viral genotype did not play a
role. However, the latter could be simply due to the
small number of cases in the study. Variations in the
IL28B gene have been identified as key predictors of
peg-IFN and ribavirin treatment response in independ-
ent genome-wide association studies, but these initial
findings were confirmed in numerous studies [52–54].
The biological mechanism behind the influence of IL28B
polymorphism on treatment outcome remains unclear,
but it was found that the CC variant is associated with
low-level expression of intrahepatic interferon-
stimulated genes [55].
Conclusion
In conclusion, we found that pretreatment activation of
the immune system, as measured by PBMC cytokines
gene transcription levels, correlates with treatment out-
come and closely reflects liver inflammatory activity.
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